Serum Raman spectroscopy as a diagnostic tool in patients with Huntington's disease

Anna Huefner1,2, Wei-Li Kuan2, Sarah L Mason2

  • 1Department of Chemistry , University of Cambridge , Lensfield Road , Cambridge , CB2 1WE , UK.

Chemical Science
|March 20, 2020
PubMed

Insights

Researchers used Raman spectroscopy techniques to analyze serum from Huntington's disease (HD) patients. Surface-enhanced Raman spectroscopy (SERS) identified spectral biomarkers correlating with disease progression, offering potential for patient stratification and monitoring.

Area of Science:

  • Neurodegenerative disease research
  • Biomarker discovery
  • Spectroscopic analysis

Background:

  • Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder.
  • Caused by CAG expansion in the huntingtin (HTT) gene.
  • Current disease progression tracking lacks objective biomarkers.

Purpose of the Study:

  • To explore spectral profiles of serum from HD patients and healthy individuals.
  • To identify potential spectral biomarkers for HD progression using Raman spectroscopy (RS) and surface-enhanced Raman spectroscopy (SERS).
  • To assess the utility of SERS and RS for patient stratification and disease monitoring.

Main Methods:

  • Collected serum samples from healthy participants and HD patients across various disease stages.
  • Utilized surface-enhanced Raman spectroscopy (SERS) and Raman spectroscopy (RS) to generate spectral profiles.
  • Analyzed spectral data for genotype- and gender-specific segregation and correlations with disease progression.

Main Results:

  • Both SERS and RS showed genotype- and gender-specific segregation in the spectral fingerprint region.
  • SERS identified significant correlations between spectral intervals and HD progression.
  • Serum molecules related to protein misfolding and nucleotide catabolism were associated with disease progression from pre-manifest to advanced HD.

Conclusions:

  • Raman spectroscopy-based techniques show potential for stratifying HD patients.
  • SERS can provide spectral biomarkers to track disease status in Huntington's disease.
  • Findings suggest potential clinical applications for other diseases and therapeutic trials.